Mivavotinib
- Generic Name
- Mivavotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21FN6O
- CAS Number
- 1312691-33-0
- Unique Ingredient Identifier
- 8QR88H79VX
- Associated Conditions
- -
- Associated Therapies
- -
Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 2
- Registration Number
- NCT05319028
- Locations
- 🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸Toledo Clinic Cancer Center, Toledo, Ohio, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT03756818
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath